Radiation-induced brachial plexus toxicity after SBRT of apically located lung lesions

Authors

  • Karin Lindberg Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden;  Section of Head, Neck, Lung and Skin tumors, Department of Cancer, Karolinska University Hospital, Stockholm, Sweden
  • Vitali Grozman Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden;  Section of Thoracic Radiology, Department of Radiology, Karolinska University Hospital, Stockholm, Sweden
  • Sara Lindberg Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden;  Department of Cancer, Karolinska University Hospital, Stockholm, Sweden
  • Eva Onjukka Section of Radiotherapy Physics and Engineering, Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden
  • Ingmar Lax Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden;  Section of Radiotherapy Physics and Engineering, Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden
  • Rolf Lewensohn Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden;  Section of Head, Neck, Lung and Skin tumors, Department of Cancer, Karolinska University Hospital, Stockholm, Sweden
  • Peter Wersäll Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden;  Section of Radiotherapy, Department of Cancer, Karolinska University Hospital, Stockholm, Sweden

DOI:

https://doi.org/10.1080/0284186X.2019.1601255

Abstract

Purpose: To evaluate the rate and dose response of brachial plexus toxicity post stereotactic body radiation therapy (SBRT) of apically situated lung lesions.

Material/methods: We retrospectively identified all patients with apically located tumors, defined by the epicenter of the tumor being located superiorly to the aortic arch, and treated with SBRT between 2008 and 2013. Patients with a shorter follow-up than 6 months were excluded. Primary aim was to evaluate radiation-induced brachial plexopathy (RIBP). Dose to the plexus was assessed by a retrospective delineation of the brachial plexus on the CT used for treatment planning. Then, DmaxD0.1ccD1cc and D3.0cc of the brachial plexus were collected from the dose-volume histograms (DVH) and recalculated to the biologically effective dose (BED) using α/β = 3 Gy. A normal tissue complication probability (NTCP) model, based on four different dose-volume parameters (BED3,max, BED3,0.1cc, BED3,1.0cc, BED3,3.0cc) was fitted to the data.

Results: Fifty-two patients with 56 apically located tumors were identified. Median prescription dose per fraction was 15 Gy (range 6–17) and median number of fractions was 3 (3–10). With a median follow-up of 30 months (6.1–72) seven patients experienced maximum grade 2 (scored 3 times) or 3 (scored 4 times) RIBP after a median of 8.7 months (range 4.0–31). Three patients had combined symptoms with pain, sensory and motor affection and four patients had isolated pain. Median BED3,max for the patients experiencing RIBP was 381 Gy (range 30–524) versus BED3,max of 34 Gy (range 0.10–483) for the patients without RIBP. The NTCP models showed a very high predictive ability (area under the receiver operating characteristic curve (AUC) 0.80–0.88).

Conclusion: SBRT of apically located lung lesions may cause severe neurological symptoms; for a three-fraction treatment, we suggest that the maximum dose to the plexus should be kept ≤30 Gy (130 Gy BED3).

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2023-10-30

How to Cite

Lindberg, K., Grozman, V., Lindberg, S., Onjukka, E., Lax, I., Lewensohn, R., & Wersäll, P. (2023). Radiation-induced brachial plexus toxicity after SBRT of apically located lung lesions. Acta Oncologica, 58(8), 1178–1186. https://doi.org/10.1080/0284186X.2019.1601255